{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-015847","form_type":"8-K","ticker":"CGC","cik":"0001737927","company_name":"Canopy Growth Corp","filed_at":"2025-02-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.669848+00:00","generated_at":"2026-05-27T00:59:48.321232+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Canopy Growth Reports Q3 FY2025 Results: Revenue Down 5%, Adjusted EBITDA Improves 61%","bullets":["Net revenue was $74.8M, down 5% YoY but up 8% excluding divestitures.","Canada medical cannabis net revenue rose 16% to $19.6M; Storz & Bickel revenue up 19% to $22M.","Adjusted EBITDA loss improved 61% to $3.5M; net loss from continuing operations was $121.9M.","Total debt reduced to $442M from $554M at September 30, 2024, after early term loan prepayment.","Claybourne infused pre-rolls launched in Canada, reaching #3 market share in BC and Ontario within 6 weeks."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-015847","json":"https://secwatch.observer/filing/0000950170-25-015847.json","markdown":"https://secwatch.observer/filing/0000950170-25-015847.md","text":"https://secwatch.observer/filing/0000950170-25-015847.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737927/000095017025015847/0000950170-25-015847-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737927/000095017025015847/cgc-20250207.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-27T00:59:48.321232+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}